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THE COST OF CLEAR SKIN: BALANCING THE SOCIAL AND
SAFETY COSTS OF IPLEDGE WITH THE EFFICACY OF
ACCUTANE (ISOTRETINOIN)
Ami E. Doshi ∗
The Food and Drug Administration (“FDA” “Agency”) continues
to face one of the most intractable issues of its tenure: deciding
whether and when efficacious treatments that may harm fetuses
1
should be available on the market. Currently, the Agency weighs the
benefits of such medication with the risk of fetal malformation, factoring the expected reduction of risk accomplished with the utiliza2
tion of risk management programs. These risk management programs seek to decrease the occurrence of fetal exposure by
facilitating the distribution of educational materials and limiting drug
3
access among women of child-bearing age. This is best illustrated by
the current debate raging within medical circles regarding the FDA’s
4
decision to allow Accutane and its generic equivalents to remain on
the market, while attempting the third in a series of flawed risk management programs to prevent the birth of children with disabilities
due to drug exposure. As implemented, the Accutane risk management program is inadequate to accomplish its goals of eliminating fetal exposure, and represents an unacceptable incursion on women’s
autonomy to decide the course of their medical care. Consequently,
∗

J. D. Candidate, 2007, Seton Hall University School of Law; Pharm. D., 2004,
Ernest Mario School of Pharmacy, at Rutgers, The State University of New Jersey.
The author would like to thank her parents, Anil and Ann Doshi, her sister, Ashley,
and David Simunovich for their invaluable support throughout her legal education.
Additionally, the author would like to thank Dean Kathleen Boozang for challenging
and encouraging her with respect to this Comment.
1
See JEFFERY E. FETTERMAN ET AL., A FRAMEWORK FOR PHARMACEUTICAL RISK
MANAGEMENT 7 (Food and Drug Law Institute 2003).
2
Id.
3
Id. at 7, 8.
4
Throughout this Comment Accutane and its generic equivalents are collectively referred to as Accutane or isotretinoin. Since Accutane did not have generic
competition until the implementation of the S.M.A.R.T. risk management program,
the use of Accutane, instead of the generic name isotretinoin, after the introduction
of generics is done solely to avoid confusion.
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the FDA should remove Accutane and its generic equivalents from
the market.
Some medications present such a serious risk to fetuses that the
FDA has advised manufacturers to provide warnings accompanying
the medication to ensure that pregnant women or those of child5
bearing age do not take or come in contact with the drug. Labeling
warnings on products is just one mechanism advocated by the FDA to
manage risk through educating patients about the drug’s effect in
6
pregnancy. For example, Propecia, which treats hair loss in men,
has such a high potential for mutative effects in fetuses that prescription bottles contain warnings alerting women who may be pregnant
7
to avoid handling the medication if tablets are broken.
Recently, the FDA has approved much more aggressive and formalized risk management programs like S.T.E.P.S., A System for Thalidomide Education and Prescribing Safety, to ensure the safety of
8
pregnant women and women of child-bearing potential. Thalido5

See FETTERMAN, supra note 1. Medications known to be teratogens and therefore contra-indicated in pregnancy include: androgens, anticonvulsants, antineoplastics, diethlystillbestol, etretinate, iodides, isotretinoin, lithium, live vaccines, methimazole, penicillamine, tetracyclines, and warfarin. JOSEPH T. DIPIRO, ET AL.,
PHARMACOTHERAPY 1302 (4th ed. 1999). Medications suggested to be teratogens and
therefore have warnings against use in pregnancy include: angiotension converting
enzyme inhibitors (ACE-I), benzodiazepines, estrogens, oral hypoglycemics, progestogens, and quinolones. The FDA has approved these medications with warnings,
concerning their risk in pregnancy. Id.
6
See FETTERMAN, supra note 1.
7
CHARLES F. LACY, ET AL., DRUG INFORMATION HANDBOOK 481 (Lexi-Comp 2001);
Merck, Propecia homepage, http://www.propecia.com (last visited Jan. 3, 2007).
Propecia (Finasteride) is a medication useful in the treatment of male pattern baldness. Id.
Women who are or may potentially be pregnant must not use Propecia
and should not handle crushed or broken Propecia tablets because the
active ingredient may cause abnormalities of a male baby’s sex organs.
If a woman who is pregnant comes into contact with the active ingredient in Propecia, a doctor should be consulted. Propecia tablets are
coated and will prevent contact with the active ingredient during normal handling, provided that the tablets are not broken or crushed.
Merck, Propecia homepage, http://www.propecia.com (last visited Jan. 3, 2007).
8
Center for Drug Evaluation and Research, FDA Announces Approval of Drug
for Hansen’s Disease (Leprosy) Side Effect; Imposes Unprecedented Authority to
Restrict Distribution, http://www.fda.gov/cder/news/thalinfo/ (last visited Jan. 9,
2007).
On July 16, 1998, FDA approved the use of thalidomide for the treatment of the debilitating and disfiguring lesions associated with erythema nodosum leprosum (ENL), a complication of Hansen’s Disease,
commonly known as leprosy. Because of thalidomide’s potential for
causing birth defects, FDA invoked unprecedented regulatory authority
to tightly control the marketing of thalidomide in the United States. A
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mide was first marketed in Western Europe in the late 1950s for the
treatment of morning sickness in pregnancy and for use as a sleeping
9
pill. At the time, its teratogenic effect was unknown until women
exposed to the medication delivered infants with horrific birth de10
fects, including mutation of limbs. The FDA immediately denied
11
In reapproval of this drug for marketing in the United States.
sponse to the appalling effects of Thalidomide, Congress enacted legislation requiring pharmaceutical manufactures to prove the efficacy
12
of a drug product to obtain FDA approval.
In a remarkable turn around, in 1998 the FDA approved Tha13
lidomide for the treatment of lesions associated with leprosy. The
FDA conditioned approval upon the manufacturer’s implementation
14
of S.T.E.P.S., a stringent risk management program that includes
requiring female patients of reproductive age to undergo pregnancy
testing and contraception counseling, the company to maintain a patient registry, and manufacturers to control distribution to authorized
15
prescribers and pharmacies. Thalidomide’s resurgence epitomizes
the challenge of balancing risks and benefits of efficacious treatments
that carry significant safety risks.

System for Thalidomide Education and Prescribing Safety (S.T.E.P.S)
oversight program has been initiated that includes limiting authorized
prescribers and pharmacies, extensive patient education about the risks
associated with thalidomide and a 100% patient registry. This oversight program is designed to help insure a zero tolerance policy for
thalidomide exposure during pregnancy.
Id.
9
Center for Drug Evaluation and Research, Frequently Asked Questions and
Answers about Thalidomide, http:/www.fda.gov/cder/news/thalinfo/ (last visited
Jan. 9, 2007).
10
See Janet Woodcock, FDA’s Medical Review of Thalidomide Clinical Development, http://www.fda.gov/cder/news/thalinfo/20785medr.htm (last visited Jan. 9,
2007).
11
Id.
12
Id. Kefauver-Harris Drug Amendments passed to ensure that a drug was not
only safe for human use but also effective in treating a proposed indication. Id. For
the first time, drug manufacturers were required to prove to FDA the effectiveness of
their products before marketing them. Id.
13
Center for Drug Evaluation and Research, supra note 8.
14
Letter from Murray M. Lumpkin, Deputy Center Dir., Center for Drug Eval.
and Research, to Steve Thomas, Celgene Corporation (July 16, 1998) (on file with
the FDA), available at http://www.fda.gov/cder/foi/appletter/1998/20785ltr.pdf.
15
Memorandum from Carl Kraus, Medical Officer, Division of Special Pathogen
and Immunologic Drug Products, to Anne Trontell, Deputy Director, Office of Drug
Safety at the Department of Health and Human Services (Jan. 29, 2004) (on file with
the FDA), available at http://www.fda.gov/ohrms/dockets/ac/04/briefing/4017B106b%20Overview%20STEPS%20Section%20C%20Tab%207.pdf.
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And yet, the FDA’s approach only manages risk; it does not
eliminate it. In the same year that the FDA approved S.T.E.P.S, the
Agency also permitted the introduction of Accutane, a drug used to
16
treat severe acne but shown to cause birth defects. Six years after
market introduction, Accutane’s manufacturer, Hoffman-La Roche,
designed the Pregnancy Prevention Program (“PPP”) to prevent
pregnancy exposures from Accutane in response to concerns about
17
birth defects. PPP required disbursement of educational materials
about avoiding pregnancy while on the medication, periodic pregnancy testing, and evidence of contraceptive use or abstinence by fe18
males of child-bearing age. The program did not yet include a man19
datory patient registry or controlled distribution like S.T.E.P.S. The
inadequacy of these precautions is poignantly illustrated by events
that occurred in 1999, when a twenty-five year old woman obtained a
prescription for Accutane from her dermatologist for treatment of se20
vere acne. The patient began Accutane therapy without waiting for
menstruation, as indicated in the patient literature about the pro21
gram requirements for women of reproductive age. Despite having
had a negative pregnancy test before starting the medication and using two forms of contraception during sexual intercourse, the patient
had a positive pregnancy test after taking the medication for one
22
23
month. Her infant was born with multiple anomalies. After cardiac surgery and extensive medical treatment for nine weeks, the in24
fant died.

16

See Woodcock, supra note 10.
See FDA, Background of Isotretinoin Teratogenic Risk Management Plan at 1,
http://www.fda.gov/ohrms/dockets/ac/04/briefing/4017B102%20%20AC%20Intro%20Review%20-Section%20A%20Tab1.pdf (last visited Jan.
9, 2007) [hereinafter Background of Isotretinoin]; see Eileen Enny Leach, MPH,
Targeted Pregnancy Prevention Program for Women on Accutane, Presentation to
the FDA (Sept. 18, 2000) available at http://www.fda.gov/ohrms/dockets/ac/
00/slides/3639s1j.ppt..
18
Leach, supra note 17.
19
Id.
20
See Accutane-Exposed Pregnancies—California 1999, 49 MORBIDITY & MORTALITY
WKLY. REP. 28, 30–31 (Jan. 21, 2000) [hereinafter Accutane-Exposed].
21
Id. at 29–31. Waiting until menstruation before initiating treatment is a preventative measure to confirm a woman has not conceived from the time of her pregnancy test to the first day of therapy. Id.
22
Id.
23
Id.
24
Id.
17

DOSHIFINAL

2007]

1/12/2007 1:45:54 PM

COMMENT

629

25

This case, which is one of many, illustrates the grave consequences of a risk management program that fails. Failures occur
most frequently because of noncompliance by the patient who neglected to read the program information and by the physician who
26
did not counsel the patient on the program requirements. Imposing even greater restrictions to avoid knowingly giving birth to a child
with severe deformities due to drug exposure creates a proverbial
Gordian knot—how does one create a program that grants access to a
life-changing drug, while simultaneously regulating its use to prevent
27
the occurrence of fetal exposure?
This Comment analyzes the FDA’s reliance on risk management
programs to balance public health with patients’ access to medical
innovation by focusing on the most recent iteration of such programs, iPLEDGE for Accutane and its generic equivalents. Part I of
this Comment provides a general review of Accutane’s FDA approval
history, reports of fetal harm from exposure to the drug, and past Accutane risk management programs that failed to sufficiently minimize
fetal exposure. Part II is broken into two sections discussing the social and safety costs of the iPLEDGE program. The first section examines the program’s implications for women of child-bearing potential. This section provides a brief history of limiting women’s health
care decisions based on child-bearing age and then analyzes how
iPLEDGE provisions affect such women. The second section discusses the safety implications of iPLEDGE, specifically illustrating
how this program will not achieve the goal set by the FDA to eliminate pregnancy exposures to Accutane. Finally, Part III concludes
that iPLEDGE is inadequate for fulfilling the FDA’s role in protecting
public health by permitting access to unsafe medication under the
guise of a counterproductive and intrusive monitoring program.
Having Accutane available on the market has great social and safety
costs that outweigh its effectiveness in treating severe acne. Therefore, the medication should not be available to the general public.
The FDA should not allow flawed risk management systems to mask a
manufacturer’s inability to produce a safe product.

25

See e.g. Accutane-Exposed, supra note 20; M.A. Honein, et. al., Continued Occurrence of Accutane-Exposed Pregnancies, 64 TERATOLOGY 142, 143 (2001).
26
Accutane-Exposed, supra note 20; Continued Occurrence of Accutane-Exposed Pregnancies, supra note 25, at 143.
27
See Bernadine Healy, Pledging for Accutane, U.S. NEWS & WORLD REP., Sept. 5,
2005, at 63; Laurel N. Geraghty, Doctors Fear Acne Drug Rules Go Too Far, N.Y. TIMES,
Jan. 12, 2006.
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AN OVERVIEW OF ACCUTANE’S APPROVAL HISTORY

In 1982, the FDA approved Hoffman-La Roche’s (“Roche”) Ac28
cutane for the treatment of severe nodular acne. This type of acne
produces cysts on the face and body from bacteria developing in increased numbers, stimulating the inflammatory process, and producing lesions with a diameter of five millimeters or greater, which can
29
produce severe scarring. The duration of Accutane treatment is fifteen to twenty weeks and results in partial to complete remission of
30
cyst-forming acne.
From 1982-2000, over five million Americans
took Accutane, with 19.8 million prescriptions dispensed from
31
United States pharmacies. Since that time, generic versions of the
drug have been on the market, resulting in lower prices and greater
32
accessibility. While even severe acne is undeniably far from a life
threatening condition, Congress heard testimony in 2002 while investigating the safety of Accutane that illustrated how life altering this
33
Some patients referred to the
treatment has been for patients.
34
medication as a “miracle drug.” A former Accutane patient, David
Shove, recounted:
28

Center for Drug Evaluation and Research, Label and Approval History of Accutane (Isotretinoin) NDA #018662, http://www.accessdata.fda.gov/scripts/cder/
drugsatfda/index.cfm?fuseaction=Search.Label_ApprovalHistory#apphist (last visited
Jan. 9, 2007) (approval occurred on May 7, 1982).
29
Id.
30
Id.
31
Diane K. Wysowski et al., Use of Isotretinoin (Accutane) in the United States: Rapid
Increase from 1992 through 2000, 46 J. AM. ACAD. DERMATOLOGY 505, 506 (2002);
Mitchell et al., An Assessment of the Accutane Pregnancy Prevention Program, Presentation at the FDA Dermatologic Drugs Advisory Committee Meeting (Sept. 18,
2000).
32
Center for Drug Evaluation and Research, Therapeutic Equivalents of Accutane (Isotretinoin) NDA #018662, http://www.accessdata.fda.gov/scripts/cder/
drugsatfda/index.cfm?fuseaction=Search.Generics (last visited Jan. 9, 2007). There
are currently three generic versions of Accutane, which all have the same active ingredient isotretinoin. Id. These generic products include: Amnesteem manufactured by Genpharm, FDA approval on Nov. 8, 2002; Claravis manufactured by Barr,
FDA approval on Apr. 11, 2003; and Sotret manufactured by Ranbaxy, FDA approval
on Dec. 24. 2002, Jun. 20, 2003. Id.
33
Issues Relating to the Safety of Accutane: Hearing Before the Subcomm. on Oversight
and Investigations of the H. Comm. on Energy and Commerce, 107th Cong. 107–143 (2002)
(The investigation of Accutane by the Subcommittee was prompted after reports of
birth defects, depression and suicides related the drug’s use. Representative Stupak,
member, House Comm. on Energy and Commerce, lost his son from suicide, possibly related to Accutane use.).
34
Id. (statement by Dr. Diane S. Berson, Associate Director of Dermatology at
Cornell University).
Accutane has been called a “miracle drug” by many patients who
have suffered from the pain and embarrassment of acne. It has
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I endured severe acne during my high school years. . . . I was
fixated upon the idea that my classmates were consumed by my
“freakish” appearance. I was embarrassed at times to be seen. I
avoided all cameras . . . and image capturing experiences. I refrained from attending events during the most heinous of breakouts. I loathed the idea of presenting in front of any type of
group. . . . While all these ideas may seem simple and, in the
grand scheme of the universe, unimportant, I assure you to a 17year-old growing up, one’s physical appearance is life-defining.
Accutane does not grow self-confidence genes, it does not develop
assertiveness cells, it simply clears one’s skin. It is through this ba35
sic task, that Accutane did, in fact, change my life.

A. Risk Management from Accutane Drug Approval to S.M.A.R.T.
(1982-2000)
The FDA first reviewed Accutane’s clinical data in 1981 when
36
Roche filed a New Drug Application (NDA). At this time, Roche
submitted animal testing data to the FDA illustrating birth defects in
37
animal offspring. In addition, the manufacturer reported no hu38
man birth defects in clinical trials. As a result, the manufacturer
recommended that warnings be included within Accutane labeling
39
However, the
cautioning women about this possible side effect.
changed the lives of so many young adults who were forced to avoid interactions with their peers at the very age when association awareness
peaks.
In the last 15 years I have prescribed Accutane to hundreds of patients. So many individuals are grateful that I was able to offer them
medication which cleared a condition many had suffered with for years
....
Id.
35

Id. (statement of David Shove, former Accutane patient).
Center for Drug Evaluation and Research, supra note 28.
37
Jill Riepenhoff & Mark D. Somerson, Company Soft-Pedaled Accutane Tie to Birth
Defects in 1982, COLUMBUS DISPATCH, May 19, 1996, at 2D.
38
Id.
39
Id. Roche recommended approval of Accutane labeling with a Pregnancy
category C designation. Id. Pregnancy category C is used “[i]f animal reproduction
studies have shown an adverse effect on the fetus, if there are no adequate and wellcontrolled studies in humans, and if the benefits from the use of the drug in pregnant women may be acceptable despite its potential risks.”
21 C.F.R. §
201.57(c)(9)(i)(A)(3). Pregnancy category A is used “[i]f adequate and wellcontrolled studies in pregnant women have failed to demonstrate a risk to the fetus
in the first trimester of pregnancy (and there is no evidence of a risk in later trimesters) . . . .” 21 C.F.R. § 201.57(c)(9)(i)(A)(1) (2006). Pregnancy category B is used
“[i]f animal reproduction studies have failed to demonstrate a risk to the fetus and
there are no adequate and well-controlled studies in pregnant women . . . .” 21 C.F.R.
§ 201.57(c)(9)(A)(2). Pregnancy category D is used “[i]f there is positive evidence of
36
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manufacturer failed to inform the Agency of the precautions taken to
40
avoid pregnancy exposure in the clinical trials. Some clinical trials
excluded women completely while others required women to be on
41
oral contraception and undergo pregnancy testing.
One woman
42
Unaware of
became pregnant but decided to have an abortion.
these details, the FDA made no additions to the label educating
43
women about the details of these clinical trials. The FDA did refer
the animal testing data to its Dermatologic Drugs Advisory Committee (now called the Dermatology and Ophthalmic Drugs Advisory
44
Committee) to recommend additional pregnancy warnings.
After reviewing the NDA and referring it to an advisory committee, the Agency approved the medication after only nine months.
Due to the drug’s effectiveness in the treatment of severe acne, the
45
FDA accelerated the approval process. Consequently, Accutane was
46
approved in 1982. The drug was designated a pregnancy category X
medication, an FDA code indicating that the risk of the drug in
47
pregnancy outweighs any benefit it may have.

human fetal risk based on ad-verse reaction data from investigational or marketing
experience or studies in humans, but the potential benefits from the use of the drug
in pregnant women may be acceptable despite its potential risks (for example, if the
drug is needed in a life-threatening situation or serious disease for which safer drugs
cannot be used or are ineffective) . . . .” 21 C.F.R. § 201.57(c)(9)(A)(4). Finally,
pregnancy category X is used “[i]f studies in animals or humans have demonstrated
fetal abnormalities or if there is positive evidence of fetal risk based on adverse reaction reports from investigational or marketing experience, or both, and the risk of
the use of the drug in a pregnant woman clearly outweighs any possible benefit (for
example, safer drugs or other forms of therapy are available) . . . .” 21 C.F.R. §
201.57(c)(9)(A)(5).
40
Riepenhoff & Somerson, supra note 37, at 2D.
41
Id.
42
Jill Riepenhoff & Mark D. Somerson, Patient was Urged to Get an Abortion; Researcher Feared Defects in Accutane User’s Baby, COLUMBUS DISPATCH, April 8, 1996, at 1C.
43
Background of Isotretinoin, supra note 17, at 1.
44
Dr. Colonel Evans, FDA Medical Group Leader, Speaker at the Dermatologic
Drugs Advisory Committee Open Session (May 8, 1989) (transcript available at
http://www.fda.gov/ohrms/dockets/ac/accutane/29t1.pdf).
45
Penny Chorlton, FDA Outpaced Firm on Acne Drug, WASH. POST, Sept. 13, 1982,
at 56 (Accutane had been classified by the FDA as “1A,” meaning it was top priority
for approval. The quick turnaround time from submission of NDA to approval surprised Roche who took an extra four months to prepare the drug for launch to the
public.).
46
Center for Drug Evaluation and Research, supra note 28 (approval occurred on
May 7, 1982).
47
Background of Isotretinoin, supra note 17, at 1; 21 C.F.R. § 201.57(c)(9)(A)(14).
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Shortly thereafter, the company received voluntary reports of
48
pregnancy from Accutane users and disclosed the cases to the FDA.
Consequently, the FDA advised Roche to make additions to pregnancy warnings, which included sending “Dear Doctor” letters and
creating red warning stickers to be used at pharmacies to alert pa49
tients of the pregnancy risk. Despite the effort to bolster patient
warnings and make reports to doctors, the manufacturer and the
FDA continued documenting instances of infants being born with
50
Accutane embryopathy malformations.
For example, in February of 1988, Dr. Godfrey Oakley wrote the
FDA stating,
I know that because the product is effective against cystic acne
that removing the drug from the market will not be popular. On
the other hand, I know that 40 infants born alive after the first
trimester exposure to Accutane have died as infants or children
because of the developmental errors that Accutane caused. I believe if 40 teenagers or young adults with acne had died as a result
of therapy caused by this drug that the drug would [be] viewed as
51
too dangerous, even though effective, to be on the market.
48
Memorandum from Dr. Edward Lammer, FDA Epidemic Intelligence Service
(EIS) Officer, to Drs. Godfrey P. Oakley and Jose Cordero, Centers for Disease Control staff (July 29, 1983) (on file with the FDA), available at
http://energycommerce.house.gov/107/hearings/12112002Hearing755/2.pdf.
The memorandum entitled “The Record (Teratology File)” describes how the FDA
spoke with Roche and received reports of four cases of children born with malformations from mothers who had taken Accutane in the first trimester. The record also
documented that though Roche reported in November of 1982 that:
no fetal abnormalities were reported in the Accutane clinical trials, in
fact there were no outcomes to evaluate. Of the 4 pregnancies occurring during the trials, 2 women elected to abort their fetuses, one child
was dead at 26 weeks gestation secondary to a prolapsed cord, and one
child was delivered at term and was normal. Retrospectively, it was determined that this latter mother was noncompliant and never took the
drug during her pregnancy.
Id. This document is then followed by countless letters from doctors asking the FDA
to pull the drug off the market. Id.
49
Background of Isotretinoin, supra note 17, at 1. FDA “Dear Doctor” letters are
letters mailed to physicians highlighting specific information a prescriber should be
aware of concerning a medication. See FDA, Manual of Standard Operating Procedures and Policies, SOPP 8108, http://www.fda.gov/cber/regsopp/8108.htm (last
visited Jan. 7, 2007). Usually specific warnings or contraindications are emphasized
in these letters. Id.
50
Center for Disease Control and Prevention (CDC), Current Trends Birth Defects
Caused by Isotretinoin—New Jersey, 37 MORBIDITY & MORTALITY WKLY. REP. 171–72, 177
(1988) (Embryopathy includes craniofacial, cardiac, thymic, and central nervous system malformations).
51
Letter from Dr. Godfrey P. Oakley, Jr., Dir. of Div. of Birth Defects & Developmental Disabilities Ctr. for Envtl. Health and Injury Control, Ctrs. for Disease Con-
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In addition, Dr. J. David Erickson wrote a letter to the FDA illustrating the concerns of the medical community and questioning the
52
FDA’s rationale in allowing Accutane to remain on the market. In
his letter he asked, “I would like to know what procedures were followed to arrive at an accounting of the benefits and risks of the use of
53
these drugs.”
Consequently, the FDA Dermatologic Drugs Advisory Committee
met on April 26, 1988 to discuss the reaction to reports of fetal expo54
sure and abortions associated with the use of Accutane.
At this
meeting, the FDA reported knowing of sixty-two birth defects attributed to Accutane and presented evidence suggesting that the drug
was being used by thousands of women of child-bearing potential
55
As a result, the committee recomwith less than severe acne.
mended the FDA restrict the drug’s use in one or more of the following ways: dispensing only to certain physicians, placing restrictions on
medication access, or requiring educational programs for physicians
56
to dispense the drug. Following this meeting, the FDA suggested “a
number of interventions [to Roche] the purposes of which were 1)
elimination of pregnancy exposure and 2) reduction of product us57
age to that specified in the labeling.”
After discussions with the FDA concerning the advisory commit58
tee’s suggestions, Roche introduced the PPP in 1988. This program
comprised of package warning labels, an informed consent form, an
informational kit for prescribers, a tracking study to access prescribers’ use of the kit, and a voluntary patient enrollment survey (the Bos-

trol, to Dr. Gerald Faich, FDA staff (Feb. 1, 1988) (on file with the FDA), available at
http://energycommerce.house.gov/107/hearings/12112002Hearing755/3.pdf.
52
Letter from Dr. J. David Erickson, Chief, Birth Defects and Genetic Diseases
Branch, Div. of Birth Defects & Developmental Disabilities at the Ctr. for Envtl.
Health and Injury Control, Ctrs. for Disease Control, to Dr. James Bilstad, FDA Staff
(Mar. 17, 1988) (on file with the FDA), available at http://energycommerce.
house.gov/107/hearings/12112002Hearing755/4.pdf.
53
Id.
54
FDA, Isotretinoin (Accutane) Birth Defects Update at 1, Apr. 26, 1988,
http://www.fda.gov/bbs/topics/ANSWERS/ANS00247.html (last visited Jan. 9,
2007).
55
Id. at 1.
56
Id. at 2.
57
Memorandum from Dr. David J. Graham, Medical Epidemiologist, Accutane
Monitoring Group, Dep’t of Health and Human Services, to the Chairman of the Accutane Monitoring Group, Dep’t of Health and Human Ser. at 1 (Apr. 6, 1989) (on
file with the FDA), available at http://energycommerce.house.gov/107/hearings/
12112002Hearing755/9.pdf.
58
Leach, supra note 17, at 1; Background of Isotretinoin, supra note 17, at 1.
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59

ton University Accutane Survey) to assess compliance with the pro60
gram. The change in the medication’s labeling required women of
child-bearing potential desiring a prescription for Accutane to commit either to abstaining from sexual intercourse, or to using two
methods of effective contraception simultaneously, to have a negative
pregnancy test before starting Accutane, and to wait until the second
or third day of their next menstrual period before beginning to take
61
Accutane. In addition, women were required to undergo monthly
pregnancy testing and monthly contraceptive counseling while on
62
Accutane therapy. Doctors could only prescribe a month supply of
Accutane to enforce continued evaluation and counseling of pa63
tients.
Yet, even with this program, reports of fetal exposure to Accutane continued. In an April 1989 FDA memorandum, Dr. David
Graham reported the incidence of pregnancy exposure based on reports of at least one pregnancy per 2000 women of reproductive
64
Dr. Graham also acknowledged FDA discrepancies in pregage.
nancy exposure data—“the FDA learned only a fraction of actual first
65
trimester pregnancy exposure events.” Furthermore, Graham observed that such underreporting is common with Accutane because
“the majority of Accutane pregnancy exposures end with either spontaneous or induced abortion and physicians do not customarily re66
In addition, Dr.
port such outcomes as adverse drug reactions.”
Graham articulated concern about the lack of effective, postmarketing studies by Roche to evaluate the effectiveness of the new
67
labeling change.
A year later, Dr. Graham reported the past two years illustrate
“that intensive regulation has not, cannot and will not achieve the

59

Allen A. Mitchell et al., A Pregnancy-Prevention Program in Women of Childbearing
Age Receiving Isotretinoin, 333 NEW ENG. J. MED. 101, 101–05 (July 1995) (summarizing
the Boston University Accutane Survey also referred to as the Slone Survey).
60
Leach, supra note 17. Accutane was packaged in blister packages of ten, twenty,
and forty milligram tablets with an “avoid pregnancy logo at each pill site.” Id. The
package also included the black box warning concerning birth defects and line drawings of birth defects. Id.
61
Id. This is to assure that the woman is not pregnant. Id.
62
Id.
63
Leach, supra note 17.
64
Graham, supra note 57, at 1.
65
Id. at 7.
66
Id.
67
Id. at 8.
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Agency’s goal of eliminating pregnancy exposure to Accutane.” He
further argued that the drug should be immediately removed from
the market citing that in the past year “while the Agency waited for
more complete data on the effect of its interventions to accumulate,
an additional 1900 pregnancy exposures occurred with 1500 abor69
tions and 117 children with birth defects.” Despite this memorandum and pressure from other medical research groups, including the
Centers for Disease Control and Prevention advocating the removal
of Accutane from the market, the FDA continued discussions with
70
Roche, keeping the drug on the market.
Nearly ten years later, the Roche post-marketing studies were
71
published with data on the effectiveness of the FDA interventions.
The January 2000 issue of Morbidity and Mortality Weekly Report con72
veyed details of the Boston University Accutane Survey. The survey
described 900 women who became pregnant while taking Accutane
between 1989 and 1998, a rate of three pregnancies for every 1000
73
treatments with the drug. In addition, the survey concluded a reduced pregnancy rate in 1998 of 2.1 pregnancies per 1000 females of
74
child-bearing age versus in 1989 a rate of 4.0 per 1000. Therefore,
one could infer that PPP was effective in lowering pregnancy rates
among women of child-bearing potential using Accutane. Difficulties
with the study, however, caution against such a conclusion—the survey was voluntary and struggled to recruit females to participate—

68

Memorandum from Dr. David J. Graham, Section Chief, Epidemiology Branch
of the FDA to Dir., Div. of Anti-Infective Drug Prod., Dept. of Health and Human
Serv. at 1 (May 7, 1990) (on file with FDA), available at http://energycommerce.
house.gov/107/hearings/12112002Hearing755/12.pdf.
69
Id. at 2.
70
See id.; Memorandum from Bob Nelson, Member of Accutane Monitoring
Group to Jim Bilstad, FDA Staff (Feb. 19, 1991), available at http://energycommerce.
house.gov/107/hearings/12112002Hearing755/13.pdf
(describing
continuing
communications between the FDA and Roche regarding Accutane monitoring);
Mark D. Somerson, Memos Bare FDA Split Over Accutane, COLUMBUS DISPATCH, July 14,
1996, at 7C (reporting that the FDA and Roche met twenty-three times between 1982
and 1991 to discuss Accutane).
71
Accutane-Exposed, supra note 20, at 28–31 (reporting unpublished 1999 data
from the Boston University Accutane Survey); Nelson, supra note 70, at 1–4 (reporting slow progress enrolling patients in the study probably due to it being a volunteer
survey).
72
Accutane-Exposed, supra note 20, at 28–31.
73
Id.
74
Id. (data implies that PPP was effective in lowering the rate of pregnancies).
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therefore it did not provide an accurate comparison of pregnancy
75
rates.
During this same time, Accutane’s popularity was growing exponentially, largely due to Roche’s advertising as well as doctors over76
prescribing the medication. According to the Centers for Disease
Control and Prevention’s study (“CDC study”), the number of “Accutane prescriptions doubled from fewer than 750,000 prescriptions in
1989 to more than 1,800,000 prescriptions in 1999” with around half
77
of the prescriptions being written for women in both years. Furthermore, the CDC study hypothesized that as Accutane use in
women of child-bearing potential increases, more Accutane-exposed
78
pregnancies can be expected.
Through the Accutane survey and Roche Drug Safety database,
the FDA compiled a review of individual pregnancy reports to un79
cover reasons for Accutane-exposed pregnancies. According to the
prescriber tracking survey, ninety-seven percent of physicians used at
80
least one component of the PPP. However, the FDA review uncov81
ered instances of patient confusion about timing of pregnancy tests,
patient misunderstanding of contraceptive methods, lack of monthly
pregnancy testing and contraceptive counseling, and instances of pa82
An
tients receiving more than a month supply of medication.
evaluation of the reports also found the following reasons why
women became pregnant: unsuccessful abstinence, ineffective or inconsistent contraception use, unexpected sexual activity, and contra83
ceptive failure.
75

See Nelson, supra note 70, at 2–3. Regardless of the study’s critiques, the FDA
used three pregnancies per 1000 Accutane women patients as a factor in calculating
success rates of risk management programs. See Accutane-Exposed, supra note 20, at 26.
76
See M.A. Honein, L.J. Paulozzi & J.D. Erickson, Continued Occurrence of AccutaneExposed Pregnancies, 64 TERATOLOGY 142, 143 (2001).
77
Id.
78
Id. at 145.
79
See Leach, supra note 17.
80
Id.
81
Id. The timing of a pregnancy test refers to the methods used to prevent false
negatives. Id. This also includes having a woman wait, even if her pregnancy tests
are negative, until her second or third day of menses before starting Accutane. Id.
This is another preventive measure taken to assure a woman is not pregnant. Id.
82
Leach, supra note 17.
83
Id. According to data presented which was based on the FDA reports and
Roche’s database, fourteen percent of women were pregnant at the time of initial
visit and twelve percent did not wait until the next menses before starting treatment.
Id. This suggests a failure in pregnancy testing. In addition, the breakdown of pregnancy occurrences during therapy is the following: Eleven percent “reported they
believed they would be able to maintain abstinence”, thirty-four percent “reported
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Also at this time, the FDA received individual case reports highlighting PPP’s ineffectiveness due to noncompliance among both pa84
tients and physicians. One report related to inappropriate prescribing by a physician to a thirty-five-year-old woman for the prevention
85
of oily skin before menstruation. The physician did not counsel her
86
about or recommend contraception. Though she used an intrauterine device, she became pregnant after taking Accutane for three
87
years. Because she had taken two doses of Accutane since her last
menstrual period, she terminated the pregnancy, stating, “the sole
88
reason for the decision was the exposure.” Another case involved a
fifteen-year-old girl whose physician refilled her Accutane prescrip89
tion despite her having missed the required monthly pregnancy test.
90
Her pregnancy was confirmed at the next month’s appointment.
While the patient used oral contraception previously, she was not tak91
The patient
ing any during the time of the exposed pregnancy.
“elected to terminate the pregnancy, stating that Accutane exposure
92
was a factor in her decision.”
As a result of the post-marketing studies, analysis of the data, and
various discussions, the FDA Dermatologic and Ophthalmic Drugs
Advisory Committee on September 18, 2000, recommended that
Roche integrate an additional five components into its risk management program to further the FDA’s goal in eliminating pregnancy
exposures among Accutane users: adopt a heightened educational
program for each patient “that includes verifiable documented written informed consent”; require “complete registration of all patients”; call for “complete registration and certification of practitioners who prescribe Accutane”; devise a comprehensive program to
track fetal exposures to Accutane (and outcomes), including a formal
mandatory pregnancy registry; and “link dispensing of Accutane to

failure to use contraception on the perceived day of conception” (thirty-three percent of these patients were only using one form of contraception), and fifty-one percent “reported contraception failure” (sixty-one percent of these patients were using
one form of contraception). Id.
84
See Honein, supra note 76, at 146; Accutane-Exposed, supra note 20, at 29.
85
Honein, supra note 76, at 147.
86
Id.
87
Id.
88
Id.
89
Id.
90
Id.
91
Honein, supra note 76, at 147.
92
Id.
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93

female patients [to] verification of adequate pregnancy testing.”
Concerned about infringing privacy rights and creating too cumber94
some of a program, Roche only incorporated two of these suggestions in its enhanced risk management program—S.M.A.R.T., System
95
to Manage Accutane Related Teratogenicity.
B. Risk Management from S.M.A.R.T. to iPLEDGE (2001-2005)
The FDA approved the enhanced risk management program,
S.M.A.R.T., in fall 2001, and the program was put into effect by April
96
2002. The FDA announced two main goals of the S.M.A.R.T. program: that no pregnant woman should begin Accutane therapy and
97
“no pregnancies should occur while a woman is taking Accutane.”
The FDA indicated that even a single fetal exposure would be unacceptable, yet both the Agency and Roche recognized that the goal of
98
eliminating all fetal exposure might not be possible. The FDA did
not set specific benchmarks in its approval of the program, but instead informed Roche that “[t]he adequacy of S.M.A.R.T. will be a re99
Emphasizing
view issue for re-evaluation on a continuing basis.”
that Roche did not incorporate all of the FDA advisory committee
100
recommendations, the Agency accepted this pregnancy prevention
93
Letter from Dr. Janet Woodcock, Dir., Ctr. for Drug Eval. and Research, to Dr.
Russell Ellison, Chief Med. Officer, Vice President, Med. Affairs, Hoffman-La Roche,
Inc. (Oct. 6, 2000), available at http://energycommerce.house.gov/107/hearings/
12112002Hearing755/24.pdf; Background of Isotretinoin, supra note 17, at 1.
94
Background of Isotretinoin, supra note 17, at 2.
95
See Hoffman-La Roche, Accutane Label Revision at 9–10 (Oct. 30, 2001) (on file
with the FDA),
available at http://www.fda.gov/cder/foi/label/2001/
18662s44lbl.pdf; Letter from Dr. Jonathan K. Wilkin, Dir., Div. of Dermatologic &
Dental Drug Prod., Ctr. for Drug Eval. and Research (CDER) to Joanna Waugh,
Group Dir., Drug Regulatory Affairs, Hoffman-La Roche, Inc. (Oct. 30, 2001) (on file
with the FDA), at 2, available at http://www.fda.gov/cder/foi/appletter/2001/
18662s44ltr.pdf.
96
Hoffman-La Roche, Accutane Label Revision (Oct. 30, 2001) (on file with the
FDA), available at http://www.fda.gov/cder/foi/label/2001/18662s44lbl.pdf; see
Background of Isotretinoin, supra note 17, at 3.
97
FDA Talk Paper, FDA Announces Changes to the Risk Management Program to Prevent
Birth
Defects
Caused
by
Accutane,
http://www.fda.gov/bbs/topics/
ANSWERS/2001/ANS01113.html (last visited Jan. 9, 2007) [hereinafter Changes to
Risk Management Program].
98
Wilkin, supra note 95, at 2. The FDA indicated that no threshold for the number of fetal exposure (greater than zero) would be acceptable during the first year of
S.M.A.R.T. Id.
99
Id.
100
See Background of Isotretinoin, supra note 17, at 2–3. The manufacturer indicated various reasons for its denial of the committee recommendations. See id.
These included rejecting a patient registry because of patient privacy issues, disagreeing with certifying physicians since the manufacturer felt it had no authority to cer-
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system contingent upon successful assessment studies, specifically
mentioning achieving greater or equal to sixty percent enrollment in
the volunteer patient survey of female patients and near 100% com101
pliance with the various program provisions.
The S.M.A.R.T program was unique in its attempt to remedy
noncompliance by both physicians and patients. To address physicians’ failure to obtain pregnancy testing, S.M.A.R.T. labeling of Accutane required that a woman of child-bearing potential have two
102
negative pregnancy tests prior to starting treatment.
To ensure
compliance, doctors had to place yellow self-adhesive Accutane
Qualification Stickers on Accutane prescriptions before a pharmacist
103
In order for a doctor to obtain these stickcould legally fill them.
ers, physicians had to read an informational booklet about S.M.A.R.T.
and return a completed Letter of Understanding to Roche confirming comprehension of the program requirements and Accutane’s risk
104
in pregnancy. This qualification sticker step required physicians to
105
assess Accutane patients before each new and refilled prescription.
In addition, S.M.A.R.T. required patients to sign informed con106
sent forms containing warnings about fetal exposure to the drug.
Women of child-bearing potential had to commit to using two forms

tify prescribers, and opposing a comprehensive program to track fetal exposures to
Accutane because of privacy concerns. See id.
101
Id.
102
Hoffman-La Roche, Accutane Label Revision (Oct. 30, 2001) (on file with the
FDA), available at http://www.fda.gov/cder/foi/label/2001/18662s44lbl.pdf.
[Female patients of childbearing potential] [m]ust have had two
negative urine or serum pregnancy tests with a sensitivity of at least 25
mIU/mL before receiving the initial Accutane prescription. The first
test (a screening test) is obtained by the prescriber when the decision is
made to pursue qualification of the patient for Accutane. The second
pregnancy test (a confirmation test) should be done during the first
five days of the menstrual period immediately preceding the beginning
of Accutane therapy. For patients with amenorrhea, the second test
should be done at least 11 days after the last act of unprotected sexual
intercourse (without using 2 effective forms of contraception). Each
month of therapy, the patient must have a negative result from a urine
or serum pregnancy test. A pregnancy test must be repeated every
month prior to the female patient receiving each prescription.
Id. at 2–3.
103
Id. at 2. The doctor must indicate on the sticker the patient’s gender, cut-off
date for filling the prescription, and up to a thirty-day supply of the medication with
no refills. If the patient was a woman, the doctor must, in addition, write the date of
qualification as determined from the last pregnancy test taken. Id.
104
Id.
105
Id.
106
Hoffman-La Roche, supra note 102, at 2.
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107

of effective contraception simultaneously unless they committed to
108
Under this new program, all women under“absolute abstinence.”
went monthly pregnancy tests while on Accutane therapy along with
monthly consultation about contraception and behaviors associated
109
To track the program’s effecwith an increased risk of pregnancy.
tiveness, the FDA required the manufacturer to conduct follow-up
studies and to report the adequacy of the program to the Agency af110
ter the first year of implementation.
Further complicating matters, by the time S.M.A.R.T. was put
into effect in April of 2002, Roche’s patent had expired and two ge111
neric medications had entered the market.
Amnesteem manufactured by Genpharm was placed on the market on November 2002
and Sotret, manufactured by Ranbaxy, was approved in December
112
Similar to Accutane, these forms of isotretinoin were ap2002.
proved with accompanying risk management programs, all possessing
113
the essential elements of Accutane’s S.M.A.R.T. program.
Nonetheless, the medical community’s concern with the risk of Accutaneexposed pregnancies increased as these more affordable generic versions became available. A comment in a Canadian medical journal
was typical: “[t]he introduction of generic forms of isotretinoin, together with decreasing prices, will further increase the use of this
114
drug by sexually active women.”

107

Id. at 3. Effective forms of contraception include both primary and secondary
forms of contraception. Primary forms include: tubal ligation, partner’s vasectomy,
intra-uterine devices, birth control pills, and topical/implantable/insertable hormonal birth control products. Id. Secondary forms of contraception include diaphragms, latex condoms, and cervical caps; each must be used with a spermicide. Id.
108
Id. “Absolute abstinence” is the wording taken directly from the package label,
implying the patient will be compliant in her pledge to abstain from sexual intercourse. See id.
109
Hoffman-La Roche, supra note 102.
110
Id. at 10–12.
111
Gideon Koren, Marina Avner & Neil Shear, Generic Isotretinoin: A New Risk for
Unborn Children, 170 CAN. MED. ASS’N J. 1567, 1567–68 (2004).
112
Id.; Center for Drug Evaluation and Research, supra note 32.
113
Koren et. al., supra note 111. Celegene, the manufacturer of Thalomid,
branded Thalidomide and obtained patents for the creation of S.T.E.P.S. Id. In order for Accutane and generic equivalents to use a similar risk management program,
isotretinoin manufacturers licensed the risk management programs from Celegene.
Id. Without getting into patent infringement details, isotretinoin companies were
able to form similar programs without the risk of infringing S.T.E.P.S. Id. at 1568.
These generic companies followed Hoffman-La Roche’s lead by adopting the essential elements of the S.M.A.R.T. system for their products. Id.
114
Id.
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These concerns proved valid. The FDA estimated total actual
115
pregnancy exposures during the first year of S.M.A.R.T. at 548.
The S.M.A.R.T. post-marketing survey results reported a pregnancy
116
rate of 3.5 out of 1000 female patients of child-bearing potential.
In sum, the S.M.A.R.T. program did not achieve its two goals. More
strikingly, the pregnancy rates post-S.M.A.R.T. remained similar to
117
the pre-S.M.A.R.T. rates.
The House of Representatives Committee on Energy and Commerce addressed issues relating to Accutane safety on December 11,
2002, hearing testimony about the benefits of the drug in cases of severe acne along with reports regarding the drug’s horrific effect in
118
pregnancy as well as alleged links to depression and suicide.
Congressional and media attention along with case reports of
S.M.A.R.T.’s ineffectiveness prompted a joint meeting on February 26
and 27, 2004, of the Dermatology and Ophthalmic Drugs and Drug
119
The
Safety and Risk Management FDA Advisory Committees.

115
Drs. Sidney M. Wolfe & Sherri Shubin, Pub. Citizen’s Res. Group, Presentation
to the FDA Drug Safety and Risk Mgmt. and Dermatologic and Opthalmic Advisory
Comms. (Feb. 26, 2004), available at http://www.fda.gov/ohrms/dockets/ac/
04/slides/4017OPH1_01_Wolfe.ppt. This pregnancy exposure estimation is 4.6
times higher than the 120 pregnancies spontaneously reported to the FDA. Id. Numerical data used in the PowerPoint slide entitled “Estimation of Total Pregnancy
Exposures During First Year S.M.A.R.T.” was taken from an FDA report. Id.
116
Allen Brinker, Cynthia Kornegay & Parivash Nourjah, Trends in Adherence to a
Revised Risk Management Program Designed to Decrease or Eliminate Isotretinoin-Exposed
Pregnancies, 141 ARCH DERMATOLOGY 563, 568 (2005). Enrollment for the S.M.A.R.T.
post-marking survey began six months after the initiation of S.M.A.R.T. Id.
117
Background of Isotretinoin, supra note 17, at 4. (“Regarding fetal exposures,
although elimination of all exposures is the goal of the risk management program, it
was understood that achievement of this might not be possible. Hence no threshold
for the number of fetal exposures (greater than zero) that would be ‘acceptable’ during the first year of S.M.A.R.T. implementation was prespecified.”).
118
See Issues Related to the Safety of Accutane, supra note 33. Representative Bart Stupak of Michigan’s First Congressional District and member of the House Committee
of Energy and Commerce lost his son to suicide in May of 2000. His son was taking
Accutane. The FDA, in February of 1998, stated in a memorandum the adverse
events that had been reported from the use of Accutane. The memorandum showed
that there were thirty-one cases of suicide, suicide attempt or suicide ideation that
were associated with the use of Accutane. Of that number, twelve were suicides, nine
of them male, two female, and one unknown, and the median age was seventeen.
The average onset of the suicidal event was eighty-eight days after the patient had
started on the prescribed use of Accutane. As the FDA memorandum stated: “[f]or
the majority, there was no antecedent history of depression, and the patients were
not noted or known to be depressed at the time period prior to their suicide.” Id.
119
Letter from Dr. Jonca Bull, Dir., Office of Drug Eval. of CDER & Dr. Anne
Trontell, Deputy Dir., Office of Drug Safety of CDER, to Dermatology and Ophthalmic Drugs and Drug Safety and Risk Mgmt. Advisory Comm. members and guests
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committees looked at prescription compliance and patient surveys,
concluding that isotretinoin-exposed pregnancies continue to occur
120
While data from
even after the implementation of S.M.A.R.T.
Roche showed better percentages in its patients and physicians’ com121
pliance, pregnancies continued to occur at an alarmingly high rate.
With an observed pregnancy rate of 3.5 to 1000, it appeared that
S.M.A.R.T.’s results were similar to those reported before the pro122
gram was put into place. One presenter summarized her view:
The S.M.A.R.T. program is clearly a failure. . . . It is time to end
the more than twenty years of voluntary restrictions that have
failed to reduce its prescribing for more than twenty times as
many women as would be using the drug if it were limited to the
123
approved indications.

After reviewing the data, the advisory committees recommended
strengthening the risk management program to include mandatory
registration of all prescription recipients and to make a negative
pregnancy test a condition to prescription dispensing for female pa124
Heeding the committees’ rectients who can become pregnant.
ommendation, Roche and generic companies created the iPLEDGE
125
126
program. The FDA approved the program on August 15, 2005.
(Feb. 2, 2004) (on file with FDA), available at http://www.fda.gov/ohrms/dockets/
ac/04/briefing/4017B100%20Bull%20Trontell%20cover%20letter%20.pdf.
120
FDA, Dermatology and Ophthalmic Drugs and Drug Safety and Risk Mgmt.
Advisory Comm. (Feb. 26 2004), available at http://www.fda.gov/oc/advisory/
accalendar/2004/cder12535dd02262704.html.
121
Results from Accutane Survey—Abstracted from Roche Quarterly Report
Submission (Jun. 30, 2002), available at http://energycommerce.house.gov/107/
hearings/12112002Hearing755/52.pdf. The compliance data illustrates: signed consent form ninety-five percent (compared to eighty-nine percent pre-S.M.A.R.T.),
postponed Accutane until results of pregnancy test known eighty-nine percent
(compared to seventy-eight percent pre-S.M.A.R.T.), postponed Accutane until next
menstrual period fifty-one percent (compared to forty-six percent pre-S.M.A.R.T.),
and pregnancy test taken prior to starting Accutane ninety-two percent (compared to
eight-four percent pre-S.M.A.R.T.). Id.
122
Dr. Allen Brinker, Isotretinoin Pregnancy Prevention Program Evaluation,
Presentation to FDA (Feb. 26, 2004) (on file with FDA), available at
http://www.fda.gov/ohrms/dockets/ac/04/slides/4017S1_07_Brinker.ppt.
123
See Wolfe & Shubin, supra note 115.
124
FDA, Dermatology and Ophthalmic Drugs and Drug Safety and Risk Mgmt.
Advisory Comm. (Feb. 27 2004) (on file with FDA), available at http://www.fda.gov/
ohrms/dockets/ac/04/transcripts/4017T2.htm.
125
The companies filed a supplemental new drug application (SNDA) under 21
CFR § 314.520, with restrictions to assure safe use. This regulation acknowledges
that while Accutane is safe and effective for some patients it imposes a risk to others.
It also enables drug companies to keep their products on the market by restricting
distribution of the drug to a patient population that will benefit from the drug’s
therapeutic effectiveness while diminishing the occurrence of the drug’s side effect.
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iPLEDGE, the third-generation of an Accutane risk management
program, tracks the distribution of Accutane by requiring that only
wholesalers registered with iPLEDGE can obtain isotretinoin from
the manufacturers and only registered pharmacies can receive medi127
cation from these registered wholesalers.
In addition, only doctors
128
registered with the program can prescribe the medication. For prescribers to register in the program, the doctor must agree to be responsible for pregnancy counseling of female patients of child129
Prebearing potential, as detailed in the guide for practitioners.
scribers also must obtain and enter patient information into the
iPLEDGE system (via the internet or phone) before writing a pre130
For women of child-bearing potential, the doctor must
scription.
record monthly pregnancy test results, confirm that the patient received monthly counseling, and enter the patient’s two chosen forms
131
of contraception each month into the iPLEDGE database.
Female patients of reproductive age must also register with the
iPLEDGE program and access the system monthly to answer questions about the program requirements and to input their two chosen
132
These women also must sign a specific informs of birth control.
formed consent about birth defects before starting isotretinoin ther133
apy. This form is in addition to the general informed consent form
134
The informed consent perthat all isotretinoin patients must sign.
taining to birth defects is comprised of thirteen affirmative state21 C.F.R. § 314.520 (2000); Letter from Dr. Florence Houn, Dir., Office of Drug
Eval. III of CDER, to Ellen Carey, Senior Program Manager of Hoffman-La Roche
(Aug. 12, 2005) (on file with FDA), available at http://www.fda.gov/
cder/foi/appletter/2005/018662s056ltr.pdf.
126
Letter from Dr. Florence Houn, supra note 125.
127
Center for Drug Evaluation and Research, Label of Accutane (Isotretinoin)
NDA
#018662
at
19,
23,
http://www.fda.gov/cder/foi/label/2005/
018662s056lbl.pdf (last visited Jan. 9, 2007). The iPLEDGE program is detailed in
the label of Accutane as well as the generic equivalents. iPLEDGE program website,
https://www.ipledgeprogram.com/ (last visited November 16, 2006). iPLEDGE is
the risk management program for all isotretinoin products and therefore the
iPLEDGE database is operated by a collaboration of these manufacturers. Id.
128
Center for Drug Evaluation and Research, supra note 127, at 20–22.
129
Id.
130
Id.
131
Id. The two forms of contraception mentioned include the choice of abstinence. Id.
132
Id. at 23.
133
Center for Drug Evaluation and Research, supra note 127, at 23.
134
Id. at 23, 36–39. There are twelve questions in the general informed consent
where a patient must acknowledge the drug’s side effects. The questions mainly pertain to reporting and identifying symptoms of depression while on the medication,
and reading and understanding the patient educational material. Id. at 36–39.
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ments, next to which the patient must initial her name.
of these statements are:

135

Examples

3. I understand that I must avoid sexual intercourse completely,
or I must use 2 separate, effective forms of birth control (contraception) at the same time.
...
11. I must stop taking isotretinoin right away and call my doctor if
I get pregnant, miss my expected menstrual period, stop using
birth control, or have sexual intercourse without using my 2 birth
control methods at any time.
12. . . . If I become pregnant, I agree to be contacted by the
iPLEDGE program and be asked questions about my pregnancy. I
also understand that if I become pregnant, information about my
pregnancy, my health, and my baby’s health may be given to the maker of
136
isotretinoin and government health regulatory authorities. . . .

If such a patient is under eighteen, in addition to her signature, her
137
parent or guardian and doctor must sign the form.
II. THE SOCIAL AND SAFETY COSTS OF IPLEDGE
iPLEDGE permits access to medication causing severe fetal de138
formities under the guise of a protective program but is in fact a
counterproductive, inefficient, and intrusive monitoring system. Inexplicably, the FDA has continued to allow a medication to remain
on the market with repeatedly inadequate risk management programs that fail to ameliorate the immense safety and social costs
139
caused by Accutane.
The FDA continues to treat the risk management of Accutane like other drugs with similar risk management programs. However, such an approach is inadequate because the patient
population being treated with Accutane is much broader than other
140
medications with similar risk management programs.
135

Id.
Id. at 37–38 (emphasis added).
137
Id. at 36.
138
Center for Drug Evaluation and Research, supra note 127, at 24.
139
See Background of Isotretinoin, supra note 17, at 1; Brinker, supra note 122.
140
See infra section II.B. The FDA has approved risk management programs for
other medications with the potential to cause birth defects. Thalomid is FDA approved for the treatment of severe erythema nodosum leprosum, which is a form of
leprosy occurring in immunocompromised patients. Celegene, Thalomid,
http://www.thalomid.com/steps_program.aspx (last visited Jan. 9, 2007). Since Thalomid has a history of horrific side effects in fetuses, the drug is managed by
S.T.E.P.S. Id. While S.T.E.P.S. requires pregnancy testing and use of oral contraception, it does not have detailed informed consents and follow-up procedures like
iPLEDGE. Id. Another medication with a risk management program is Tracleer,
FDA approved for the treatment of pulmonary arterial hypertension. Tracleer,
136
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The FDA articulates an unwillingness to accept a greater than
zero tolerance for pregnancy rates occurring with Accutane use, yet
allows the drug’s existence on the market after continuously receiving reports of pregnancies under previous risk management pro141
grams.
iPLEDGE will not eliminate fetal exposures to Accutane
and it does not achieve the FDA’s desired balance between protecting
142
future life and keeping an effective medication on the market.
In
fact, this program implements draconian measures aimed at preventing pregnancy but creates even more problems that should be unacceptable to the FDA. The social implications of the iPLEDGE provisions on women of child-bearing potential will be explored first.
Thereafter, a discussion of the safety costs associated with Accutane
available on the market will be analyzed.
A. The Social Cost of Impeding a Woman’s Autonomy in Medical
Treatment Decisions
Accutane’s availability through iPLEDGE promotes viewing
women solely on their status as child bearers. iPLEDGE limits
women’s autonomy and defeats the purpose of having the medication
143
on the market, to make available effective treatment to patients.
iPLEDGE improperly regulates a woman’s choice to bear children
144
and take the risk of having children with birth defects.
History illustrates how profound a step backward iPLEDGE takes public policy
and how high a social cost it generates.

http://www.tracleer.com/
default.asp?page=OnTrac_WhatsTracleer (last visited Jan. 9, 2007). Tracleer has a
high potential for birth defects and is managed through a closed distribution system
called the Tracleer Access Program (T.A.P.). Tracleer, http://www.tracleer.com/
default.asp?page=HCP_Prescribe (last visited Jan. 9, 2007). T.A.P. regulates patients’
access to the medication by centralizing the drug distribution to only four specialty
pharmacies after a physician approves of its use in a patient. Patient Enrollment—
T.A.P., http://www.tracleer.com/dot/TAP%20Patient%20Enrollment%20Form.dot
(last visited Jan. 9, 2007).
141
See Changes to Risk Management Program, supra note 97.
142
Riepenhoff & Somerson, supra note 37. Due to noncompliance issues, loopholes in the iPLEDGE program and illegal use of the medication, sexually active
women could use isotretinoin and become pregnant. Past risk management programs have failed. See Wilkin, supra note 95. iPLEDGE mandates will decrease instances of abuse but will not eliminate them. Perfection is impossible. Id.; See Center
for Drug Evaluation and Research, supra note 127.
143
See Center for Drug Evaluation and Research, supra note 127; Geraghty, supra
note 27.
144
See Int’l Union v. Johnson Controls, Inc., 499 U.S. 187, 211 (1991).
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The History of Limiting a Woman’s Autonomy Based
on Her Childbearing Potential

A woman’s autonomy is often compromised because of her potential for pregnancy. Individual autonomy is valued as a fundamental right derived from the Constitution and generally supersedes state
145
However, there are
actions restricting such personalized freedom.
instances when even this well-protected and valued fundamental right
146
of autonomy is sometimes limited.
The government’s interest in
women of child-bearing age is to protect the potential for future
147
While this interest becomes heightened when a woman is
life.
pregnant and a fetus is viable, the interest is ambiguous when a
woman’s rights are being limited solely based on her status as a
148
Without delving into a discussion of
woman of reproductive age.
149
the various contexts where a maternal-fetal conflict arises, the following discussion will briefly highlight the treatment of women based
on childbearing potential throughout history.
Historically, courts would allow limiting women from employment opportunities based on being weak and fragile, existing only to
150
serve a domestic role and bear children.
Lawyers and lawmakers
exploited perceived differences between the genders like intelligence, behavior, physical appearance, social construct, hormonal
makeup, and psychological characteristics as support for treating
151
women differently. Ultimately, the differential treatment of women
152
stemmed from their potential to bear children.

145

See generally CYNTHIA DANIELS, AT WOMEN’S EXPENSE: STATE POWER AND THE
POLITICS OF FETAL RIGHTS 24 (Harvard Univ. Press 1993).
146
Id. at 15–35.
147
Id.
148
Id.
149
See generally Daniels, supra note 145, at 24. This term refers to the relationship
between a mother and fetus. Id. The federal government and various state governments have addressed situations where fetal rights outweigh a woman’s choice. Id.
In the context of forced medical intervention, criminal prosecution, and even abortions, there are instances where the government will interfere with the choices of a
mother to protect the fetus. Id. Since this discussion of the social cost of iPLEDGE
concerns women not yet pregnant, a discussion of the maternal-fetal context would
be too broad. Id.
150
See Julianna S. Gonen, Removing Informed Consent from HIV Testing of Pregnant
Women: A Return to the Maternal-Fetal Conflict, 2 GEO. J. GENDER & L. 765, 775–76
(2001).
151
Id. at 775–77.
152
Id.
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153

Bradwell v. Illinois illustrates a vivid portrayal of women treated
as potential child bearers. In Bradwell, the Supreme Court of the
United States held that the right to practice law was not a privilege or
immunity protected by the Fourteenth Amendment and denied a
154
woman from obtaining a license to practice law.
Justice Bradley in
his concurrence wrote, “The paramount destiny and mission of
women are to fulfill the noble and benign offices of wife and mother.
This is the law of the Creator. And the rules of civil society must be
adapted to the general constitution of things, and cannot be based
155
on exceptional cases.”
Thirty-five years later, a similar portrayal of
156
women appeared in the Supreme Court case Muller v. Oregon. This
case denied establishing a maximum-hour law for male bakers since it
interfered with the freedom to contract yet upheld such a law for
women due to the government’s public interest in preserving the
157
The Court further stated that even when a
health of women.
woman is not pregnant it is imperative to safeguard her health “as
healthy mothers are essential to vigorous offspring, the physical wellbeing of woman becomes an object of public interest and care in or158
der to preserve the strength and vigor of the race.”
Title VII of the Civil Rights Act of 1964 changed the analysis of
the above cases, prohibiting employment discrimination on the basis
159
of race, color, religion, sex, and national origin.
Soon afterwards,
the Pregnancy Discrimination Act in 1978 was passed, extending the
Title VII definition of “sex” to encompass pregnancy and related
160
However, another debate began over “fetal
medical conditions.
161
protection policies” instituted by employers. These policies banned
women of child-bearing potential from working with toxic substances
162
that could affect or harm a developing fetus.

153

83 U.S. (16 Wall.) 130 (1873), abrogated by Planned Parenthood v. Casey, 505
U.S. 833, 896 (1992).
154
Id. at 138–39.
155
Id. at 141–42 (1873) (Bradley, J., concurring).
156
Muller v. Oregon, 208 U.S. 412 (1908).
157
Id. at 420–22.
158
Id. at 421.
159
42 U.S.C. § 2000 (2000).
160
Id. at § 2000e.
161
See REGINA H. KENEN, REPRODUCTIVE HAZARDS IN THE WORKPLACE: MENDING JOBS,
MANAGING PREGNANCIES 16 (Harrison Park Press 1993); SALLY J. KENNEY, FOR WHOSE
PROTECTION? REPRODUCTIVE HAZARDS AND EXCLUSIONARY POLICIES IN THE UNITED
STATES AND BRITAIN 12 (University of Michigan Press 1992).
162
See KENEN, supra note 161, at 16; KENNEY, supra note 161, at 12.
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In International Union v. Johnson Controls, Inc. the Supreme
Court held that sex-specific fetal-protection policies are forbidden
164
under Title VII of the Civil Rights Act. The case examined a battery
manufacturing company’s policy of excluding women of reproductive
165
age from jobs where lead exposure was possible.
Though this case
was determined in the context of employment-based discrimination,
Justice Blackmun described the danger in treating all women of re166
In addition, he mentioned that fetal
productive age as pregnant.
167
Addressing the disparity in
safety was best left to the mother.
treatment between women of reproductive age and other employees
of the battery company, Judge Blackmun explained that the law does
168
The majority connot accept such discrimination under Title VII.
cluded by maintaining that “[i]t is no more appropriate for the courts
than it is for individual employers to decide whether a woman’s reproductive role is more important to herself and her family than her
economic role. Congress left this choice to the woman as hers to
169
make.”
Despite Johnson Controls, companies continued instituting fetal170
protective polices.
While some companies felt tort liability outweighed anti-discrimination suits by keeping fetal-protective policies
in place, other companies refused to acknowledge the hazards to re171
production and evaluated situations on an individualized basis.
Even still, a few companies altered their policies to facially comply
172
with Title VII.
For example, the company Exide established a policy that required all women employees to attend a training session
about lead exposure, which consisted of watching a video advocating
that women should avoid jobs where exposure to lead was a possibil173
The video also explained the adverse effects of lead exposure
ity.
163

499 U.S. 187 (1991).
42 U.S.C. § 2000 (2000).
165
Int’l Union v. Johnson Controls, Inc., 499 U.S. 187, 190 (1991).
166
Id. at 198.
167
Id. at 206.
168
Id. at 210.
169
Id. at 211.
170
See Elaine Draper, Reproductive Hazards and Fetal Exclusion Policies after Johnson
Controls, 12 STAN. L. POL’Y REV. 117, 119 (2001); Nicole G. Hoeksma, Regulating
Risk: Reproductive Toxins in the Workplace in Post-Johnson Controls Era, 14 S. CAL. REV. L.
& WOMEN'S STUD. 289, 289 (2005).
171
Draper, supra note 170, at 121.
172
Id.
173
Suzanne U. Samuels, The Lasting Legacy of International Union, U.A.W. v. Johnson Controls: Equal Employment and Workplace Health and Safety Five Years Later, 12 WIS.
WOMEN’S L.J. 1, 8–9 (1997).
164
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174

on reproduction.
Men working at the company were never made
175
aware of these adverse affects.
Pharmaceutical research is another area in which women of
child-bearing potential were excluded and their health disadvantaged
176
because of their gender.
For years the FDA excluded women from
177
clinical trials in order to protect reproductive capabilities.
This attitude of “protectionism” stemmed from a desire to avoid prior research abuse in what is frequently referred to as a “vulnerable” popu178
However in 1993, President Clinton signed the National
lation.
Institutes of Health Revitalization Act requiring the inclusion of
women in clinical trials to ensure comprehensive analysis in re179
search. Consequently, the FDA policies were updated to encourage
the inclusion of women participants, including those of reproductive
180
While the Agency has not mandated that
age, in research studies.
drug companies include women of child-bearing potential, the FDA
has acknowledged the benefit of studying medication effects on con181
senting women.
While the employment and research contexts differ from the
treatment context, the issues presented in Johnson Controls and in the
FDA’s past research policies parallel issues that arise when a woman
182
of reproductive age is subjected to the mandates of iPLEDGE.
iPLEDGE treats women of child-bearing potential differently than
183
other patient populations.
The program treats all women as preg184
Instead of allownant regardless of their choice to bear children.
ing a woman to make her own choices about contraception and the
risk of pregnancy, the government and manufacturer dictate what a

174

Id.
Id.
176
See
FDA,
FDA
Scholarship
in
Women’s
Health
Program,
http://www.fda.gov/cber/clinical/femclin.htm (last visited Jan. 9, 2007) [hereinafter FDA Scholarship]; FDA, Executive Summary—Gender Studies in Product Development, http://www.fda.gov/womens/gender/Exec4.htm (last visited Jan. 9, 2007)
[hereinafter Executive Summary].
177
See FDA Scholarship, supra note 176; Executive Summary, supra note 176.
178
See FDA Scholarship, supra note 176; Executive Summary, supra note 176.
179
See U.S. Department of Health and Human Services, National Institutes of
Health, Revitalization Act of 1993, 42 U.S.C. § 289a-2 (2000).
180
See FDA Scholarship, supra note 176; Executive Summary, supra note 176.
181
See FDA Scholarship, supra note 176; Executive Summary, supra note 176. In
addition, studies do not separate differential side effects on men and women, so
women still are not receiving the full benefit of pharmaceutical research.
182
See Draper, supra note 170, at 120.
183
See Center for Drug Evaluation and Research, supra note 127.
184
Id.
175
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woman must do and use the iPLEDGE database to monitor compli185
While trying to atance before allowing access to the medication.
tain a zero pregnancy exposure rate to the drug, the FDA creates a
restrictive program for women that may, as a result, encourage non186
compliance and increase the risk of Accutane-exposed pregnancies.
ii.

The Effect of iPLEDGE on Women of Reproductive
Age

The iPLEDGE program creates several obstacles for women of
187
While
reproductive age before gaining access to the medication.
the program’s goal, to reduce the risk of fetal anomalies, is laud188
able, its methodology is flawed—the decisions of whether to become pregnant, how to prevent pregnancy and what risks are reason189
able during pregnancy are the woman’s and hers alone.
The FDA
and drug manufacturers have an obligation to provide women with
sufficient information to make educated decisions, but not to make
190
iPLEDGE’s imposition of restrictions on
the decisions for them.
reproduction is overly inclusive in that it interferes with women’s
autonomy based on their potential to become pregnant and their pre191
The consequences of so circumscribing
sumed sexual activity.
women’s behavior and choices in their medical treatment create
more harm for fertile women than if the drug was simply unavailable.
Treating women as pregnant or sexually active, when they are not,
and making healthcare decisions on their behalf is a backwards and
unacceptable step in public policy.
iPLEDGE’s impingements on a woman’s freedom are both numerous and onerous. A woman of reproductive age must comply
with several provisions in order to obtain a month’s supply of Accu192
At her first doctor visit, she is counseled about the birth detane.
fects that could occur if she becomes pregnant, receives a pregnancy
test, is informed about registering for iPLEDGE through the elec193
tronic database, and undergoes consultation on contraception.
Regardless of her marital status, sexual orientation, personal view on
185

Id.
Id. See supra section I.B.
187
See Center for Drug Evaluation and Research, supra note 127.
188
FDA Talk Paper, supra note 97.
189
See DANIELS, supra note 145; Int’l Union v. Johnson Controls, Inc., 499 U.S.
187, 210 (1991).
190
See 21 C.F.R. §§ 201.56-.57 (2005).
191
See Center for Drug Evaluation and Research, supra note 127.
192
Id. at 23, 36–39.
193
Id. at 21–23, 25–26, 36–39.
186
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sex outside of marriage or intention to have children, she receives in194
formation and is counseled about contraception.
The potential Accutane patient must then read the consent
forms, which require her to initial after statements dictating what she
must do when engaging in sexual activity and when faced with a
195
pregnancy. One statement requires her to tell the doctor at any instance she breaks her commitment of abstinence or fails to use two
196
forms of contraception during sexual activity.
Afterward, the woman must return to her doctor for another
visit to take a second pregnancy test, confirm her initiation of treatment and receive an Accutane prescription that is voidable if not
197
Before filling the medication, the patient
filled within seven days.
must input her two forms of contraception or commitment to abstinence into the iPLEDGE database and answer questions related to
198
This database can be accessed online or via telethe program.
phone, and a woman is expected to answer and input personal information into an automated system, with no personal contact with a
199
Only after inputting this information
healthcare professional.
200
She must then
within the database is her prescription activated.
201
repeat this process for refills.
These time-consuming and private steps disregard patient202
specific issues related to women of child-bearing age.
Such steps
deter women of reproductive age who genuinely could benefit from
203
Below are examples of
taking the medication from obtaining it.
how this program unfairly treats women as “pregnant,” disregarding
194

Id.
Id. at 21–23, 36–39.
196
Id. at 38–39.
197
See Center for Drug Evaluation and Research, supra note 127, at 21, 38.
198
Id. at 23, 39. No information is available on how detailed these questions will
be or whether some questions might offend women who have pledged to abstain
from sexual intercourse or minors. See id.; iPLEDGE program website, supra note
127.
199
See id. at 23, 46; iPLEDGE Program Frequently Asked Questions,
http://www.fda.gov/cder/drug/infopage/accutane/FAQ200610.pdf (last visited
Jan. 9, 2007) at 2–3.
200
See Center for Drug Evaluation and Research, supra note 127, at 23, 46;
iPLEDGE Program Frequently Asked Questions, supra note 199, at 2–3.
201
Center for Drug Evaluation and Research, supra note 127, at 23, 38–39. Normal duration of treatment is fifteen to twenty weeks, so refills are needed. In order
to obtain a refill prescription, a woman has to repeat all the program steps except
signing the informed consent forms completed during her initial consultation. Id. at
15.
202
See supra notes 193–202.
203
Id.
195
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their choices about reproduction and sexual activity in order to
eradicate the possibility of pregnancy exposure to Accutane. Consequently, the premise of the program’s existence, to keep an effective
acne treatment on the market, is expunged when patients who could
benefit from its use do not have access to it. As a result, noncompliance becomes an easy alternative for these women to gain access, in204
creasing the possibility of Accutane-exposed pregnancies.
1.

A Woman Who Pledges Abstinence

A vivid example of iPLEDGE disregarding female autonomy in
health decisions related to reproduction and sex is the case of a
woman or young teen who pledges abstinence by religious conviction
or lifestyle choice. Through iPLEDGE, she is still required to be
counseled on contraception at the initial visit and monthly thereaf205
ter.
She must also undergo initial and monthly pregnancy test206
ing. In addition, she is required to answer questions about the pro207
gram monthly that may relate to sexual activity.
This government
mandated program forces a woman to hear instruction about activities and preventative measures that may contradict her faith or personal preference.
For example, the compelled use of two forms of contraception
violates the religious beliefs of Catholics who adhere to church teach208
ings that they may only use natural family planning. Therefore, the
program is an impediment for accessing isotretinoin. While a patient
unable to adhere to the conditions can always choose other acne
treatments for nodular acne, isotretinoin is the most effective medi209
A woman who commits to abstinence is decation on the market.
terred from treatment by the program’s rigid and possibly offensive
210
provisions. To subject such a woman to these mandates is bad public policy because the program precludes her from exercising her
choice to become pregnant and employs contraceptive approaches

204

See supra section I.B.
Center for Drug Evaluation and Research, supra note 127, at 21.
206
Id.
207
Id.
208
10 NEW CATH. ENCYCLOPEDIA 176–79 (Thomas Gale ed., Catholic University
2003). According to the labeling, natural family planning is not considered one of
the options for contraception. Center for Drug Evaluation and Research, supra note
127, at 21–22, 37.
209
See Chorlton, supra note 45; Center for Drug Evaluation and Research, supra
note 28 (approval occurred on May 7, 1982, which was a fast tracked approval due to
the drug’s clinical effectiveness).
210
See supra notes 193–202.
205
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211

that offend her religious beliefs.
This program requires a woman
who pledges abstinence to undergo additional pregnancy testing,
212
doctor visits, and potentially offensive educational sessions.
2.

A Sexually Active Woman

Another implication of iPLEDGE is the effect it has on sexually
active women, treating them as potentially pregnant. A woman who
engages in sexual intercourse should not be compelled to forego
health decisions regarding sex and reproduction as a condition of
having access to medical care. To obtain Accutane, a woman en213
gaged in sexual activity must use two forms of contraception.
This
limits the woman’s choices regarding her own health. For example,
if a woman does not agree with or has difficulty with taking hormonal
214
contraception, she may be prevented from access to Accutane.
If a woman elects to take Accutane, which requires her to consent to iPLEDGE provisions, but then chooses for whatever reason
not to comply with the contraception requirements, or has a contraceptive failure and becomes pregnant, she must include the
215
iPLEDGE program in discussions regarding her personal choices.
216
By the program’s involvement in tracking the pregnancy and providing educational services, a woman’s decision about reproduction
may be influenced by a governmentally approved program. Usually
the woman and her doctor discuss this decision. The fear of involving an unwanted but interested third party creates the potential for
abuse in affecting a person’s choice. A possible concern here could
be an opportunity for the program or the FDA to advocate for abortions, thereby reducing the number of birth defects and pregnancy
exposures to Accutane and keeping the drug on the market. While
only a possibility, the involvement of individuals other than those
whom the woman chooses raises concerns about the type of information provided to, and influences imposed upon, the patient.
3.

A Female Minor of Child-bearing Age

Similarly, a female minor of reproductive age may be discouraged from obtaining treatment due to implications regarding parental consent. A female patient of child-bearing age, but under the age
211
212
213
214
215
216

See Int’l Union v. Johnson Controls, Inc., 499 U.S. 187, 200 (1991).
See Center for Drug Evaluation and Research, supra note 127, at 21–22, 37, 39.
Id.
Id.
Id. at 39.
Id.
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of eighteen, must have her guardian or parent and doctor sign the
iPLEDGE informed consent forms before initializing acne treat217
This requires a minor not only to discuss issues regarding
ment.
her sexual activity and views on reproduction with her doctor but also
with her parent(s). In addition, a minor is exposed to Accutane
218
counseling on contraception that may be offensive to the patient or
her parent(s). Such provisions can limit or deter access to the medication at a time in life when its psychological and social benefits are
likely most acute. Furthermore, many state laws allow minors to receive sexual health treatment without parental consent, so the
iPLEDGE provisions may pose a problem in requiring parents or
guardians to sign consent forms authorizing acne treatment, which
219
include the disclosure of use of contraception.
iii. Overall Social Cost of iPLEDGE
The program’s effect on women of reproductive age takes a
backward step in public policy, treating women based on their potential to become pregnant. The FDA clearly seeks to further the laudable goal of protecting future life. While this argument has been
used in employment cases where environmental exposure effects
women’s reproductive organs, Accutane exposure is harmful to a fe220
tus. As a result, the FDA’s goal in limiting treatment for women of
child-bearing age implies that women and their doctors cannot make
decisions regarding reproduction and sexual health without the involvement of a third party, the iPLEDGE program. This assumption
interferes with the traditional patient-physician decision-making relationship, diminishes a woman’s choice, and creates a potential for
abuse by the manufacturer.
Consequently, the goal of the program’s existence, to keep an
221
effective acne treatment on the market, is lost when patients who
could benefit from its use do not have access to it. The social expense of iPLEDGE described above highlights the cost of interfering
with personal autonomy. Another problem with the iPLEDGE program is limiting a patient’s access to medication, which creates the
217

Center for Drug Evaluation and Research, supra note 127, at 36, 39.
Id. at 20–21, 25, 38–39.
219
See Rachel K. Jones, Confidential Reproductive Health Services for Minors: The Potential Impact of Mandated Parental Involvement for Contraception, 36 PERSP. ON SEXUAL &
REPROD. HEALTH 182, 186–87 (2004).
220
Center for Drug Evaluation and Research, supra note 127, at 11–12, 51–54.
221
See Marilyn R. Pitts, FDA Safety Evaluator, Presentation at the American Society
of Health-System Pharmacists Clinical Midyear (Dec. 7, 2005), available at
http://www.ashp.org/emplibrary/RiskManagementPlans.pdf.
218
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potential for abuse and subsequently unsafe use of medication. The
next section illustrates how possibilities of abuse or noncompliance
create safety concerns that outweigh the effectiveness of the Accutane.
B. The Safety Cost: Weighing the Risks and Benefits of Accutane
Congress requires the FDA to consider safety before it approves
222
a new drug for market introduction. A manufacturer must demonstrate safety with sufficient evidence when submitting a New Drug
223
Application.
While Accutane was approved by the FDA as safe and
effective in 1982, post-marketing analysis of the risk of pregnancy exposure to the drug prompted the introduction of a risk management
program as a condition of keeping the medication on the market.
Unfortunately, neither past programs nor iPLEDGE have or will
eliminate pregnancy exposures. Therefore, the safety cost of Accutane being available on the market is too great to justify its benefit as
an effective acne treatment.
The FDA bases pre-market approval of an NDA on a risk-benefit
224
analysis “for the intended population and use.” The importance of
considering the intended population with the side effects of a medication is to assess the rate of risk. For example, Thalomid (thalidomide) and Tracleer, which both cause severe birth defects in pregnant patients, are prescribed to a much narrower patient population
225
than Accutane. Therefore the ability for this risk management program to be effective is decreased when there is a broader patient
222
21 U.S.C.A. § 355(d) (West 2006). The term safe refers to “health of man or
animal.” 21 U.S.C.A. § 321 (West 2006) (“Safe” was intended to include only the inherent safety of drug when used in the manner intended.).
223
21 U.S.C.A. § 355.
224
FDA, Managing the Risks From Medical Product Use: Creating A Risk Management Framework at 21, http://www.fda.gov/oc/tfrm/riskmanagement.pdf (last
visited Jan. 3, 2007) [hereinafter Managing the Risks].
225
See Celgene, Thalomid, supra note 140; Tracleer, supra note 140. Thalomid
treats multiple myeloma and severe erythema nodosum leprosum while Tracleer
treats pulmonary arterial hypertension. See Celgene, Thalomid, supra note 140; Tracleer, supra note 140. These conditions occur in patient populations that are generally focused on fewer patients and older patients than Accutane’s intended population—adolescents and adults with severe forms of acne. See Celgene, Thalomid,
supra note 140; Tracleer, supra note 140. The risk of pregnancy in pre-menopausal,
sexually active patients creates a greater risk than in patient populations with that are
postmenopausal, immunocompromised and physically impaired by their health condition, as is generally the situation with patients being treated with Thalomid and
Tracleer. See Celgene, Thalomid, supra note 140; Tracleer, supra note 140. Also, neither Thalomid nor Tracleer is available in generic forms, thereby economically limiting patients from access to these therapies as well. See Celgene, Thalomid, supra note
140; Tracleer, supra note 140.
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population within the age range to become pregnant using the medication. Thalomid and Tracleer have a greater potential to meet the
FDA’s zero pregnancy threshold goal since the number of patients
being treated with the medication are less likely to be as sexually ac226
Thus, the
tive or able to conceive compared to Accutane patients.
Thalomid and Tracleer risk management programs have the ability to
manage the risk of birth defects, while iPLEDGE has a much harder
task.
The Agency acknowledges a safe product as one with “reasonable risks, given the magnitude of the benefit expected and the alter227
228
natives available.”
However, no drug is without side effects. The
amount of risk acceptable in light of a drug’s beneficial effect re229
mains difficult to calculate.
Clinical trials can establish scientific
data to illustrate whether a product is safe but such data does not
conclusively suggest the value judgment that ultimately must be made
230
“[S]cience alone can never be an adeas to the safety of a drug.
quate basis for a risk decision . . . risk decisions are, ultimately, public
231
policy choices.”
Keeping a beneficial medication available to patients by managing its side effects is good public policy. However, the ability to manage the side effects is key for this analysis. Risk assessment in pharmaceuticals involves the evaluation and analysis of risks associated
232
with a drug product.
Most risk management programs encompass
the following key components: identification of the problem, analysis
226

See Celgene, Thalomid, supra note 140; Tracleer, supra note 140.
See Managing the Risks, supra note 224, at 3.
228
See Celgene, Thalomid, supra note 140; Tracleer, supra note 140. “Although
medical products are required to be safe, safety does not mean zero risk, since all
medical products are associated with risks.” Managing the Risks, supra note 224, at 3.
229
In unsuccessful legislation, the FDA sought to define the term safe; “the term
‘safe’ means that the health benefits of the drug entity clearly outweigh the risks presented by the drug entity, taking into account the standards and requirements applicable to drug products . . . .” James T. O’Reilly, 1 FOOD AND DRUG ADMIN. §14:4, n.14
(quoting S. 1045, 96th Cong. (1979); S. 2755, 95th Cong. §109(E) (1978)).
230
See Managing the Risks, supra note 224.
231
NATIONAL RESEARCH COUNCIL, UNDERSTANDING RISK: INFORMING DECISIONS IN A
DEMOCRATIC SOCIETY 26 (1996).
232
FETTERMAN, supra note 1, at 116.
Risk Assessment: as it relates to healthcare, scientific evaluation of
known or potential adverse health effects resulting from human exposure to medication therapies.
Risk management: the systematic approach to setting the best
course of action, policies, processes, procedures, practices, and resources to the assessment, communication and control of risk issues affecting human health and safety.
Id.
227
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of the probability and severity of the risk, planning and communicating to control the risk, and evaluating the outcomes of interven233
tions.
The early stages of Accutane use in clinical trials illustrate the
start of a public policy debate over whether the benefits of a miraculous acne treatment outweigh the drug’s risk in causing fetal deformities. In the beginning, Accutane’s benefits outweighed its known risk
234
in pregnancy exposure. No other medication on the market cured
235
this degree of acne like Accutane. In addition, the FDA never identified Accutane’s devastating effect in human pregnancy during the
236
pre-market approval phase.
Not until post-marketing studies and voluntary patient reporting
did the FDA identify human birth defects as an unacceptable risk of
237
Accutane use.
Lack of complete data impaired the FDA’s full as238
sessment of the problem. As a result, the Agency and manufacturer
delayed implementing risk controls in order to understand where to
239
attack the problem of exposure in pregnancy. After gathering data
and observing case reports of babies born with abnormalities, the
FDA conditioned Accutane’s continued sales on a zero pregnancy
240
exposure policy. The FDA would not compromise with Roche during the pre-S.M.A.R.T. time period to set a threshold limit on pregnancy exposure, apparently in conformity with the Agency’s policy
241
against harming future life.
Nonetheless, even with the implementation of the S.M.A.R.T.
program, pregnancies still occurred as a result of noncompliance in
242
the broad patient population being treated with the medication.
243
With
This led to discussions regarding the creation of iPLEDGE.
the approval of iPLEDGE the FDA pronounces that Accutane can be
244
used safely, but only under restrictive distribution.
The FDA has
233

Id. at 68–69.
See Background of Isotretinoin, supra note 17, at 1.
235
Id. Accutane has been referred to as a “miracle drug” for its effectiveness in
the treatment of severe acne. See Issues Related to the Safety of Accutane, supra note 33
(statement by Dr. Diana S. Berson, Associate Director of Dermatology at Cornell
University).
236
Riepenhoff & Somerson, supra note 37.
237
See id.
238
See id.
239
See id.
240
See Wilkin, supra note 95.
241
Id.
242
Mitchell et al., supra note 59, at 101–06; Leach, supra note 17.
243
Center for Drug Evaluation and Research, supra note 127.
244
See 21 C.F.R. § 314.520 (2000).
234
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not attained its goal of zero pregnancy exposures, and fails to acknowledge the impossibility of obtaining complete patient adherence
to any risk management program. Since physicians may legally prescribe drugs for off-label uses, it is not possible to ensure physician
compliance to limit prescriptions only to the most severe acne cases.
While a deviation from the program could invoke regulatory sanctions and other actions, punishing a pregnant woman for conceiving
245
under iPLEDGE is harsh and impractical.
While well-intentioned, the FDA is compromising public health.
If past risk management programs were not successful in preventing
exposed pregnancies, the use of a mandatory registry will not stop
those patients too embarrassed to report their diversions to iPLEDGE
from defying the program’s mandates. The restrictive provisions of
the program will not just deter women from taking the medication
but may encourage the program’s failure. Women of reproductive
age who are sexually active may lie in their responses to the iPLEDGE
database. Minors may feel great pressure to be dishonest in discussions with their parents or guardians, fail to reveal they are sexually
active, and begin medication without any contraception. This increases the chance of an Accutane-exposed pregnancy.
Exposed pregnancies are inevitable with a medication treating a
broad patient population, suggesting that the safe use of the isotretinoin is impossible. The FDA is simply attempting to avoid this immutable reality by affirming a third-generation risk management program for isotretinoin. Allowing a woman to face the horrible choice
of having an unwanted abortion or a child with birth deformities due
to drug exposure outweighs the need for clear skin even in the most
severe cases of acne.
III.

CONCLUSION

The FDA’s unwillingness to protect future life by taking Accutane off the market (a true zero tolerance of pregnancy rates) has
simply gone on too long. As long as Accutane remains on the market, the goal of eliminating all fetal exposures will never be at246
tained.
And yet, in pursuit of this flawed goal, iPLEDGE improperly limits women’s autonomy through intrusive and ineffective
245
Center for Drug Evaluation and Research, supra note 127, at 38–39. As the
U.S. News and World Report commented, “[a]n irresponsible pregnancy, once just a
source of shame, will soon be a recordable national offense—that is if it occurs while
taking the acne drug Accutane.” Bernadine Healy, Pledging for Accutane, U.S. NEWS &
WORLD REP., Sept. 5, 2005, at 63.
246
See Pitts, supra note 221.
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provisions that are so strict that they actually encourage noncompli247
The result of nonadherence is pregnancy exposure and the
ance.
possibility of regulatory action punishing the patient. Instead of simply withdrawing the medication, the FDA limits the choice of a
woman based on her potential to become pregnant in the hopes that
this will eliminate pregnancy exposures.
The FDA’s indecision incurs social and safety costs. Yet, the FDA
has chosen to allow Accutane to remain on the market since 1982
with evidence of continued pregnancy exposures and birth defects in
children. Dr. David J. Graham of the FDA stated, “Isotretinoin is one
248
of five dangerous drugs that should be removed from the market.”
The FDA, upon due notice to the manufacturer, has the statutory authority to immediately withdraw a product from the market by revoking the product’s NDA on the grounds that the drug is an “imminent
249
hazard” to the public health. The FDA chooses iPLEDGE as the solution instead of making a tough decision regarding the value of preventing fetal exposure to Accutane. As a result, iPLEDGE “will bring
guilt, lies, and misdemeanors but no fewer pregnancies or conse250
The FDA should take action and remove Accuquent abortions.”
tane from the market before further pregnancy exposures occur.

247

Center for Drug Evaluation and Research, supra note 127.
See Issues Related to the Safety of Accutane, supra note 33 (statement by Dr.
David J. Graham of the FDA).
249
O’REILLY, supra note 229, at §13:23. The Agency can also remove the drug
from the market if:
1. The drug has been found unsafe under its labeled conditions of use,
upon experience, tests or other scientific data
2. New evidence shows that the drug is not safe for its intended and
labeled use
3. New information shows a lack of substantial evidence of effectiveness
4. The approved application is found to have an untrue statement of a
material fact.
Id.
250
Healy, supra note 245, at 63.
248

